AstraZeneca’s Farxiga Falters in Phase 3 COVID-19 Trial

AstraZeneca’s heart failure and diabetes drug Farxiga (dapagliflozin) failed to meaningfully reduce the risk of organ dysfunction and death for high-risk, hospitalized COVID-19 patients in a phase 3 study.

Launched in April 2020, the trial was the first to assess the safety and efficacy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor for hospitalized COVID-19 patients at risk of developing serious complications.

The global study, which enrolled 1,250 volunteers for a 30-day course of treatment, aimed to show if the drug would help treat co-morbidities like heart, kidney or metabolic conditions exacerbated by COVID-19.

AstraZeneca will share the full trial results next month.